

NC DHB Pharmacy Request for Prior Approval -Growth Hormone – Children Less than 21 Years of Age

Recipient Information		DMA-0017 (V.03)
1. Recipient Last Name:	2. First Name:	
3. Recipient ID #		5. Recipient Gender:
Payer Information		
6. Is this a Medicaid or Health Choice Request?	Medicaid:	Health Choice:
Prescriber Information		
7. Prescribing Provider #:	NPI:	or Atypical:
8. Prescriber DEA #:	=	
Requester Contact Information		
Name:	Phone #:	Ext:
Drug Information		
9a. Drug Name:	9b. Is this request f	
10. Strer	ıgth: 11.	Quantity Per 30 Days:
	60 90 120 180	365 Other:
Clinical Information		
1. Diagnosis:		
FOR NON-PREFERRED DRUGS COMPLETE THIS S		
	-	
2. History of: a. Turners Syndrome	b. Prader Willi Syndrom	
d. Panhypopituitarism in the last 2 years		e. Cranial Irradiation in the last 2 years
f. MRI Evidence of Hypopituitarism List:		
	ars i. <u>SGA</u> with IU	GR j. 🗌 Other:
3. Please check all that apply:	tile for Done And Haidel	Walasten
a. Patient has a height velocity < 25 th Percen	tile for Bone Age. Height	Velocity: evel: IGFBP-3 Level:
b. Patient has low serum levels of IGF-1 and	IGFBP-3 IGF-1 Le List:	evei: IGFBP-3 Levei:
c. Patient has other signs of hypopituitarism d. Patient is an adequately nourished child w		CU response to hypoglycomia
		Height: Percentile:
f. Birth weight and/or length more than 2 sta		
g. History of GHD in the last 2 years. Is there		
Stim testing? Agent 1: Agent 2:		
3. Is the epiphysis open (if patient > 9 years old)		_
	-	standard deviations below mean for age, and bone age > 2 standard
deviations below mean, and low serum levels of IGF-1 and IGFBP-3? Yes No IGF-1 Level:IGFBP-3 Level:		
5. Is the patient currently being treated? Yes		<u> </u>
6a. Growth rate over previous year: b. Has the patient entered puberty? Yes No		
7. Are IGF-1 and IGF-BP3 within age appropriate range? Yes No Results:		
Zorbitive only: 8. Is there a history of short bowel syndrome in the last 2 years? Yes No		
Increlex only: Check all that apply		
9a. History of GH product in last year	b. GH resistance is caus	ed by mutation in GH receptor of post GH receptor signaling pathway
c. 🗌 Patient has IGF-1 gene defects 🛮 d. 🔲 GH	I gene deletions and patient	has developed neutralizing antibodies to GH
e. \square Patient ht < 3 SD < mean and IGF-1 level <	3 SD < Mean and normal or	elevated GH levels.
Signature of Prescriber:		Date:

*Prescriber signature mandatory

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

Fax this form to NCTracks at: (855) 710-1969 Pharmacy PA Call Center: (866) 246-8505